Dr. Goldfine’s research focuses on identification and targeting of pathways relevant to development of type 2 diabetes, and/or complications of the disease, and in trials to develop new treatment strategies. Studies characterize gene expression in muscle, liver and adipose tissue in metabolically characterized patients to reveal novel pathways of human relevance that can be further evaluated in animal models of diabetes. Current efforts additionally focus on the role of western lifestyle to promote obesity, insulin resistance, and a chronic low grade inflammatory state that is associated with diabetes, pre-diabetes, and cardiovascular disease. She is currently Co-Principal Investigator of the nearly completed multicenter clinical studies “Targeting INflammation using SALsalate in Type 2 Diabetes (TINSAL-T2D)” and the ongoing “Targeting INflammation with SALsalate or Lifestyle in patients with CardioVascular Disease (TINSAL-CVD)”.
Dr. Goldfine’s lab has contributed to the knowledge on how bariatric surgery may promote metabolic improvement following Roux-en-Y gastric bypass, with a focus on a rare group of patients who develop hyperinsulinemic hypoglycemia several years following surgery. In study of the pathophysiology linking obesity to diabetes, and remission of disease realized by bariatric surgery procedures, she is co-Principal Investigator of the NIH sponsored ongoing trial “Surgery or Lifestyle with Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D)”.
Additionally, Dr. Goldfine serves as a voting member on the Endocrine and Metabolic Disease Advisory Committee to the Food and Drug Administration. At the Joslin Diabetes Center, she has continued to perform clinical and translational research, provide medical care for patients with diabetes, and teach at Harvard Medical School. Dr. Goldfine is now an Associate Professor of Medicine at Harvard Medical School, and Head of Clinical Research at Joslin.